Bispecific T cell receptor molecules can leverage the body’s immune system by regulating the T-cell response towards cancer cells with specific tumor targets. There are two domains of our bispecific T-cell receptor.  https://www.creative-biolabs.com/car-t/bispecific-tcr-development-service.htm

1. Bispecific T Cell Receptor
www.creative-biolabs.com/car-t

2. Bispecific TCR is a molecule that can regulate the body’s immune system by redirecting and promote the T-cell
response towards cancer cells with specific tumor targets.

3. Background
The TCR is a molecule existed on the surface of T cells, or T lymphocytes. Its responsibility is to recognize fragments of antigen to
provide peptides bound to major histocompatibility complex (MHC) molecules. The relationship between the binding TCR and
antigen peptides is unrestricted and gradually degenerated, which means that TCRs and antigen peptide are not in a biunique
relationship. Typically, the TCR is made up of two different protein chains. After being combined with antigenic peptide and
MHC (peptide/MHC complex) via TCR, the T lymphocyte will be activated through signal transduction. This is a series of
biochemical events mediated by associated enzymes, co-receptors, and specialized adaptor molecules, resulting in activation of
transcription factors.

4. Introduction of Bispecific TCR
Bispecific TCR molecules can leverage the body’s immune system by regulating the T-cell response towards cancer cells with
specific tumor targets. There are two domains of our bispecific T-cell receptor. One of them is an affinity-maturated and highly
selective TCR domain that can recognize and bind to a tumor-specific peptide target presented in the context of HLA class I
receptor, the other is a T-cell recruiting antibody domain directed against CD3 or other immuno-modulating T-cell surface proteins.
The characteristic of these novel receptors allows T cells to be activated and attack the tumor, regardless of the T cells’ intrinsic
specificity. After being administrated to the patients, our bispecific TCR will selectively bind to the surface of targeted tumor cells.
Then the bispecific TCR will recruit and activate T cells via CD3 binding initiates tumor killing.

5. Fig 1. Antigen presentation stimulates T cells with the help of TCR.

6. Features
• Ph.D. level scientists and skillful technicians
• Extensive experience
• Capable of affinity optimization
• Low off-target toxicity
• Superior quality

7. • With the exponentially increased demand in modern novel medicine, the CAR
and TCR immune cell therapy has been one of the most promising approaches
for target-specific cancer treatment. With integrated global resources in all
aspects, Creative Biolabs provides one-stop full CAR T/NK Cell therapy
development service, including early non-clinical research, process development,
pre-clinical animal model testing, cGMP manufacturing, and phase I-III clinical
trials.
About

8. Contact
• 45-1 Ramsey Road, Shirley, NY 11967, USA
• Email: marketing@creative-biolabs.com
• www.creative-biolabs.com/car-t

9. Thank You